Form 4: Incyte Executive Sells Shares Under 10b5-1 Plan

Mohamed Khairie Issa, Incyte's EVP, Head of US Oncology, reported the sale of 10,856 common shares and a tax-related withholding of 8,264 shares, both executed under a Rule 10b5-1 plan.

Summary

• Mohamed Khairie Issa, EVP, Head of US Oncology at Incyte Corp (INCY), reported transactions involving the company's common stock.
• On January 6, 2026, 8,264 shares were withheld by the Issuer to satisfy tax withholding obligations at a price of $106.66 per share.
• On January 7, 2026, 10,856 shares of common stock were sold at a price of $109.07 per share.
• Both transactions were made pursuant to a Rule 10b5-1(c) contract, instruction, or written plan.
• Following these transactions, Mr. Issa beneficially owns 66,132 shares of common stock, which includes previously reported unvested Restricted Stock Units (RSUs).

Sentiment

Score: 6

Explanation: The transactions represent routine insider activity, including tax-related withholding and a pre-scheduled sale under a 10b5-1 plan, which generally indicates a planned liquidity event rather than a reaction to new company-specific information.

Positives

• The transactions were executed under a Rule 10b5-1 plan, indicating pre-scheduled sales and reducing concerns about opportunistic insider selling.

Negatives

• A reduction in direct beneficial ownership by a key executive (10,856 shares sold).

Future Outlook

NA

Industry Context

NA

Corporate Governance

Stakeholder Impact

• Shareholders: May note the reduction in direct share ownership by a key executive, though mitigated by the 10b5-1 plan.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions, including a tax-related withholding and a pre-scheduled sale under a 10b5-1 plan. While it represents a reduction in an executive's direct holdings, the pre-arranged nature of the sale suggests it's not based on new material information. A Form 4 alone typically does not provide sufficient information to alter a fundamental investment thesis, thus a 'hold' recommendation is appropriate, pending further company-specific or market-wide developments.

Keywords

Incyte Corp, INCY, Form 4, insider transaction, stock sale, executive compensation, 10b5-1 plan, common stock, restricted stock units, tax withholding